625 related articles for article (PubMed ID: 17685465)
1. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
2. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
3. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
Nakayama H; Yoshida A; Nakamura Y; Hayashi H; Miyagi Y; Wada N; Rino Y; Masuda M; Imada T
Anticancer Res; 2007; 27(5B):3645-9. PubMed ID: 17972530
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
7. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
8. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
9. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
[TBL] [Abstract][Full Text] [Related]
10. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
11. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
12. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.
Howell GM; Carty SE; Armstrong MJ; Lebeau SO; Hodak SP; Coyne C; Stang MT; McCoy KL; Nikiforova MN; Nikiforov YE; Yip L
Ann Surg Oncol; 2011 Dec; 18(13):3566-71. PubMed ID: 21594703
[TBL] [Abstract][Full Text] [Related]
13. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
[TBL] [Abstract][Full Text] [Related]
14. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.
Howell GM; Nikiforova MN; Carty SE; Armstrong MJ; Hodak SP; Stang MT; McCoy KL; Nikiforov YE; Yip L
Ann Surg Oncol; 2013 Jan; 20(1):47-52. PubMed ID: 22941165
[TBL] [Abstract][Full Text] [Related]
16. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
Jeong D; Jeong Y; Park JH; Han SW; Kim SY; Kim YJ; Kim SJ; Hwangbo Y; Park S; Cho HD; Oh MH; Yang SH; Kim CJ
Ann Surg Oncol; 2013 Mar; 20(3):759-66. PubMed ID: 23179992
[TBL] [Abstract][Full Text] [Related]
17. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis.
Lee JH; Lee ES; Kim YS
Cancer; 2007 Jul; 110(1):38-46. PubMed ID: 17520704
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases.
Zerilli M; Amato MC; Martorana A; Cabibi D; Coy JF; Cappello F; Pompei G; Russo A; Giordano C; Rodolico V
Cancer; 2008 Sep; 113(5):936-44. PubMed ID: 18615628
[TBL] [Abstract][Full Text] [Related]
20. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
